Alnylam Pharmaceuticals, Inc. income statement

In fiscal 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71bn, up 65.2% on the year before, operating income of $502m (a 13.5% margin) and net income of $314m, or $2.33 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alnylam Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2008Dec 2008	2009Dec 2009	2010Dec 2010	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	96	101	100	47	90	75	220	493	844	1,037	1,828	2,248	3,714
Cost of revenue	—	—	—	—	0	2	25	74	115	140	268	307	677
Gross profit	—	—	—	—	90	73	195	419	729	897	1,560	1,942	3,037
Research and development	97	109	106	382	391	505	655	655	792	883	1,004	1,126	1,320
Selling, general and administrative	—	—	—	89	199	382	479	588	621	771	796	976	1,211
General and administrative	27	40	38	—	—	—	—	—	—	—	—	—	—
Operating income	−28	−48	−44	−425	−500	−815	−939	−828	−709	−785	−282	−177	502
Interest expense	1	—	—	—	—	0	0	84	143	156	121	142	253
Income before tax	−26	−47	−43	−410	−491	−761	−885	−856	−852	−1,127	−434	−377	323
Income tax	1	1	1	0	0	1	1	3	1	4	7	−99	9
Net income	−26	−48	−44	−410	−491	−761	−886	−858	−853	−1,131	−440	−278	314
Diluted EPS	—	−$0.57	−$0.52	−$4.79	−$5.42	−$7.57	−$8.11	−$7.46	−$7.20	−$9.30	−$3.52	−$2.18	$2.33
Diluted shares (average)	—	—	84m	86m	91m	101m	109m	115m	118m	122m	125m	128m	135m
EBITDA	−22	−42	−39	−409	−487	−799	−922	−794	−661	−741	−228	−120	557

US$ millions unless shown otherwise. Fiscal quarters.

Alnylam Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	501	593	594	774	1,249	1,097	1,291	1,458
Cost of revenue	82	103	70	142	197	268	298	362
Gross profit	419	491	524	632	1,052	829	993	1,096
Research and development	271	300	265	324	359	372	413	409
Selling, general and administrative	221	295	240	323	322	325	348	342
Operating income	−77	−105	18	−16	368	132	231	346
Interest expense	34	39	58	61	67	65	82	84
Income before tax	−109	−194	−2	−41	281	86	178	296
Income tax	3	−110	16	31	−12	−25	13	−1,872
Net income	−112	−84	−18	−72	293	112	164	2,167
Diluted EPS	−$0.87	−$0.65	−$0.14	−$0.55	$2.14	$0.82	$1.21	$15.72
EBITDA	−63	−91	32	−2	382	145	—	360

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALNY vs NBIX ALNY vs BMRN ALNY vs ARGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.